{"id":"dabigatran-rivaroxaban","safety":{"commonSideEffects":[{"rate":"2-4% major bleeding annually","effect":"Bleeding (major and minor)"},{"rate":"5-10%","effect":"Dyspepsia"},{"rate":"1-2%","effect":"Gastrointestinal bleeding"},{"rate":"1-3%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL198362","moleculeType":"Small molecule","molecularWeight":"435.89"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dabigatran is a direct thrombin inhibitor that blocks Factor IIa, preventing the conversion of fibrinogen to fibrin and clot formation. Rivaroxaban is a Factor Xa inhibitor that blocks the intrinsic and extrinsic coagulation pathways. Both drugs provide rapid anticoagulation without requiring monitoring, unlike warfarin.","oneSentence":"Both dabigatran and rivaroxaban are direct oral anticoagulants that inhibit key clotting factors to prevent blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:31:58.256Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Deep vein thrombosis (DVT) treatment and prevention"},{"name":"Pulmonary embolism (PE) treatment and prevention"},{"name":"Acute coronary syndrome (rivaroxaban)"}]},"trialDetails":[{"nctId":"NCT03568890","phase":"PHASE4","title":"Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","startDate":"2018-09-01","conditions":"Left Atrial Appendage Closure, Thrombosis, Stroke","enrollment":510},{"nctId":"NCT07497893","phase":"NA","title":"FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants)","status":"NOT_YET_RECRUITING","sponsor":"Ewha Womans University Mokdong Hospital","startDate":"2026-12-01","conditions":"Atrial Fibrillation (AF), Upper Gastrointestinal Bleeding (UGIB), Gastrointestinal Hemorrhage (Clinically Important, Upper)","enrollment":1000},{"nctId":"NCT05387954","phase":"PHASE3","title":"PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-07","conditions":"Cryptogenic Ischemic Stroke, Patent Foramen Ovale","enrollment":792},{"nctId":"NCT06650501","phase":"PHASE4","title":"Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2026-01-15","conditions":"Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia","enrollment":300},{"nctId":"NCT04618913","phase":"","title":"Anticoagulation in Patients With Venous Thromboembolism and Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-14","conditions":"Neoplasms, Embolism","enrollment":1},{"nctId":"NCT05038228","phase":"","title":"High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-08-01","conditions":"Atrial Fibrillation","enrollment":1},{"nctId":"NCT07242326","phase":"","title":"SNAP AF-52: Dose Appropriateness and Adherence to Oral Anticoagulation in Adults ≥65 With Atrial Fibrillation in Primary Care (Ordu, Türkiye)","status":"ENROLLING_BY_INVITATION","sponsor":"Kotyora Family Medicine Health Management and Education Association","startDate":"2025-12-15","conditions":"Medication Adherence, Atrial Fibrillation (AF), Direct Oral Anticoagulants (DOACs)","enrollment":1000},{"nctId":"NCT04611893","phase":"","title":"Monitoring of NOAC Therapy: Standardizing Reference Intervals","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2020-11-05","conditions":"Ischemic Stroke, Stroke, Acute, Stroke Syndrome","enrollment":308},{"nctId":"NCT05825573","phase":"PHASE3","title":"Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2023-05-15","conditions":"Intracardiac Thrombus, STEMI, Heart Failure","enrollment":340},{"nctId":"NCT07358416","phase":"","title":"Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Petrovsky National Research Centre of Surgery","startDate":"2025-05-01","conditions":"Thrombosis, Bleeding, Cerebral Hypoxia During and/or Resulting From A Procedure","enrollment":500},{"nctId":"NCT04045665","phase":"PHASE3","title":"Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-12-13","conditions":"Atrial Fibrillation, Stroke, Bleeding","enrollment":3200},{"nctId":"NCT07352358","phase":"PHASE4","title":"Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-01-30","conditions":"Cerebral Venous Thrombosis","enrollment":72},{"nctId":"NCT03968393","phase":"PHASE4","title":"Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2019-06-14","conditions":"Stroke, Atrial Fibrillation","enrollment":2270},{"nctId":"NCT05838664","phase":"","title":"A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-07-07","conditions":"Atrial Fibrillation","enrollment":2140403},{"nctId":"NCT03463317","phase":"PHASE4","title":"Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2018-02-28","conditions":"Atrial Fibrillation","enrollment":912},{"nctId":"NCT04684212","phase":"NA","title":"Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF","status":"WITHDRAWN","sponsor":"Brian O'Neill MD","startDate":"2024-06-01","conditions":"Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA","enrollment":""},{"nctId":"NCT04284839","phase":"PHASE3","title":"The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2021-07-18","conditions":"Bleeding Post Cardiac Surgery, Indication for Anticoagulation","enrollment":3500},{"nctId":"NCT06581965","phase":"PHASE4","title":"inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2024-11-11","conditions":"Venous Thromboembolism, Venous Thromboses, Pulmonary Embolism","enrollment":10078},{"nctId":"NCT07083609","phase":"","title":"Treatment Outcomes of Direct Oral Anticoagulants in Cerebral Venous Thrombosis in Vietnam","status":"RECRUITING","sponsor":"Hieu Trung Dinh","startDate":"2025-07-11","conditions":"Cerebral Venous Thrombosis","enrollment":69},{"nctId":"NCT05990894","phase":"","title":"Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis.","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2020-07-01","conditions":"Cerebral Venous Thrombosis","enrollment":170},{"nctId":"NCT03778502","phase":"","title":"DOAC in Unusual Site Venous Thrombosis","status":"COMPLETED","sponsor":"University of Malta","startDate":"2019-10-01","conditions":"Splanchnic Vein Thrombosis, Cerebral Vein Thrombosis, Ovarian Vein Thrombosis","enrollment":358},{"nctId":"NCT03087487","phase":"","title":"Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-06-01","conditions":"Non-Valvular Atrial Fibrillation","enrollment":466991},{"nctId":"NCT06101667","phase":"NA","title":"Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-10-15","conditions":"Acute Ischemic Stroke, Basilar Artery Occlusion","enrollment":224},{"nctId":"NCT07011095","phase":"EARLY_PHASE1","title":"DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial","status":"NOT_YET_RECRUITING","sponsor":"Population Health Research Institute","startDate":"2025-09-03","conditions":"Atrial Fibrillation (AF), Stroke (in Patients With Atrial Fibrillation)","enrollment":100},{"nctId":"NCT06983795","phase":"","title":"Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study","status":"NOT_YET_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-07","conditions":"Ischemic Stroke, Patent Foramen Ovale","enrollment":1000},{"nctId":"NCT03129490","phase":"PHASE4","title":"The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Herlev and Gentofte Hospital","startDate":"2023-04-01","conditions":"Atrial Fibrillation, Atrial Flutter","enrollment":11000},{"nctId":"NCT04700826","phase":"PHASE4","title":"Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2021-06-01","conditions":"Atrial Fibrillation","enrollment":3000},{"nctId":"NCT03129555","phase":"PHASE4","title":"The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Herlev and Gentofte Hospital","startDate":"2023-04-01","conditions":"Deep Vein Thrombosis, Pulmonary Embolism","enrollment":5000},{"nctId":"NCT06957366","phase":"NA","title":"Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-04-01","conditions":"Atrial Fibrillation (AF), VTE","enrollment":920},{"nctId":"NCT05735639","phase":"PHASE4","title":"THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2024-01-22","conditions":"Venous Thromboembolism, Varicose Veins","enrollment":6660},{"nctId":"NCT04394234","phase":"","title":"A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-05-15","conditions":"Uterine Hemorrhage","enrollment":961985},{"nctId":"NCT06449469","phase":"NA","title":"The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2021-05-01","conditions":"Aortic Valve Stenosis, Cardiovascular Diseases, Heart Diseases","enrollment":352},{"nctId":"NCT06322953","phase":"PHASE3","title":"Timing to Restart Direct Oral Anticoagulants After Traumatic Intracranial Haemorrhage","status":"RECRUITING","sponsor":"Walton Centre NHS Foundation Trust","startDate":"2025-03-10","conditions":"Traumatic Intracranial Haemorrhage","enrollment":1084},{"nctId":"NCT03504007","phase":"","title":"Registry of Patients Prescribed Anticoagulation","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2013-03-01","conditions":"Acute Deep Vein Thrombosis, Acute Pulmonary Embolism","enrollment":10000},{"nctId":"NCT06571149","phase":"PHASE4","title":"Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2025-03-14","conditions":"Ischemic Stroke","enrollment":906},{"nctId":"NCT05750680","phase":"","title":"DOCE Study Interaction Between Direct Oral Anticoagulants and Drug-metabolizing Enzyme Inducers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-05-13","conditions":"Atrial Fibrillation, Thromboembolism, Venous","enrollment":23},{"nctId":"NCT05068414","phase":"","title":"Assessment of the Incidence of Hemorrhagic and Ischemic Events in Post-angioplasty in Anticoagulated Coronary Patients with Atrial Fibrillation","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2021-04-12","conditions":"Atrial Fibrillation, Acute Coronary Syndrome, Thrombosis","enrollment":122},{"nctId":"NCT04234698","phase":"","title":"Patient Characteristics, Treatment Patterns And Incidence Of Events (Discontinuation, Persistence, Key Primary Clinical Outcomes) In NVAF Patients Initiating OAC Therapy In Colombia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-03-22","conditions":"Atrial Fibrillation","enrollment":2076},{"nctId":"NCT05378035","phase":"","title":"DOAC in Chinese Patients With Atrial Fibrillation","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2022-09-28","conditions":"Atrial Fibrillation, Stroke, Stroke, Acute","enrollment":427},{"nctId":"NCT03996772","phase":"PHASE3","title":"PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2019-06-03","conditions":"Atrial Fibrillation, Intracerebral Hemorrhage","enrollment":319},{"nctId":"NCT03062319","phase":"PHASE4","title":"Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis","status":"TERMINATED","sponsor":"National Hospital Organization Osaka National Hospital","startDate":"2017-04-06","conditions":"Ischemic Stroke, Atrial Fibrillation, Atherothrombosis","enrollment":321},{"nctId":"NCT01924065","phase":"PHASE3","title":"Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation","status":"COMPLETED","sponsor":"Suleyman Demirel University","startDate":"2013-08","conditions":"Atrial Fibrillation, Cardioversion, Cerebrovascular Stroke","enrollment":112},{"nctId":"NCT04979780","phase":"","title":"Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-07-20","conditions":"Treatment of Venous Thromboembolism in Cancer Patients, Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients","enrollment":3708},{"nctId":"NCT06615596","phase":"EARLY_PHASE1","title":"Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2025-01","conditions":"Atrial Fibrillation (AF)","enrollment":3160},{"nctId":"NCT03596502","phase":"","title":"Direct Oral Anticoagulants in Patients with Atrial Fibrillation (DOACs Vs Warfarin)","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-02-01","conditions":"Atrial Fibrillation, Ischemic Stroke, Systemic Embolization","enrollment":402764},{"nctId":"NCT04477837","phase":"","title":"Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants","status":"COMPLETED","sponsor":"Cardioangiologisches Centrum Bethanien","startDate":"2020-10-15","conditions":"Heavy Menstrual Bleeding","enrollment":84},{"nctId":"NCT06556446","phase":"","title":"Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2024-01-01","conditions":"Ischemic Stroke","enrollment":2800},{"nctId":"NCT06551402","phase":"PHASE3","title":"Dabigatran Versus Rivaroxaban in Cerebral Venous Thrombosis","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-08-09","conditions":"Cerebral Venous Sinus Thrombosis","enrollment":200},{"nctId":"NCT04249401","phase":"","title":"Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-03-01","conditions":"Atrial Fibrillation","enrollment":134897},{"nctId":"NCT06486792","phase":"PHASE4","title":"Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-09-01","conditions":"Stroke, Ischemic Stroke, Cerebral Infarction","enrollment":1148},{"nctId":"NCT04847752","phase":"","title":"Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2021-03-01","conditions":"Ischemic Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis)","enrollment":1000},{"nctId":"NCT05472766","phase":"NA","title":"Anticoagulation Therapy Timing in Atrial Fibrillation After Acute and Chronic Subdural Hematoma","status":"TERMINATED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2022-11-24","conditions":"Subdural Hematoma, Atrial Fibrillation","enrollment":1},{"nctId":"NCT06401616","phase":"PHASE4","title":"Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2024-05-21","conditions":"Atrial Fibrillation, Left Atrial Appendage Absent, Anticoagulant Adverse Reaction","enrollment":1220},{"nctId":"NCT03759938","phase":"NA","title":"OPTIMAS: OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke : a Randomised Controlled Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2019-06-18","conditions":"Stroke, Acute, Atrial Fibrillation","enrollment":3648},{"nctId":"NCT05006287","phase":"PHASE2","title":"The Safety of Non-vitamin K Oral Anticoagulants Compared to Warfarin Early After Cardiac Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Paul's Hospital, Canada","startDate":"2022-10-12","conditions":"Atrial Fibrillation","enrollment":100},{"nctId":"NCT05802576","phase":"","title":"Study of Interference Between Oral Anticoagulants and Heparin During Ablation of Atrial Fibrillation (AF) or Left Atrial Tachycardia (GAD) by Catheter.","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-07-08","conditions":"Atrial Fibrillation, Atrial Tachycardia","enrollment":100},{"nctId":"NCT06057467","phase":"NA","title":"Early Versus Late Initiation of Anticoagulation in Mild-to-moderate AIS Patients With NVAF","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-09-15","conditions":"Acute Ischemic Stroke, Atrial Fibrillation","enrollment":2351},{"nctId":"NCT06058130","phase":"NA","title":"Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-09-29","conditions":"Acute Ischemic Stroke, Atrial Fibrillation, Stenosis, Carotid","enrollment":2171},{"nctId":"NCT01613443","phase":"","title":"Ex-vivo Effect of New Oral Anticoagulants on Point-of-care Devices","status":"COMPLETED","sponsor":"Cardioangiologisches Centrum Bethanien","startDate":"2012-06","conditions":"Effect of NOAC on POCT","enrollment":100},{"nctId":"NCT05051904","phase":"","title":"A Study Based on Japanese Medical Records That Looks at Bleeding Events in People With Atrial Fibrillation and Coronary Artery Disease Who Start Taking Either Dabigatran, Rivaroxaban, or Warfarin","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-05-17","conditions":"Coronary Artery Disease, Atrial Fibrillation","enrollment":39357},{"nctId":"NCT04042155","phase":"","title":"Real-life Clinical Outcomes of Direct Oral Anticoagulants (MACACOD)","status":"UNKNOWN","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2019-07-29","conditions":"Atrial Fibrillation, Recurrent Venous Thromboembolism","enrollment":1600},{"nctId":"NCT04262492","phase":"","title":"International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants","status":"RECRUITING","sponsor":"Stéphane Zuily","startDate":"2020-10-21","conditions":"Antiphospholipid Syndrome, Thrombosis, Anticoagulants Causing Adverse Effects in Therapeutic Use","enrollment":500},{"nctId":"NCT04662515","phase":"","title":"NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications","status":"COMPLETED","sponsor":"Malmö University","startDate":"2016-06-01","conditions":"Surgery, Oral, Hemorrhage, Postoperative Complications","enrollment":216},{"nctId":"NCT05292846","phase":"PHASE4","title":"Uninterrupted Direct-acting Oral Anticoagulation in Patients Undergoing Transradial Percutaneous Coronary Procedures","status":"UNKNOWN","sponsor":"Hospital Universitario La Fe","startDate":"2022-01-20","conditions":"Coronary Artery Disease, Bleeding, Direct Acting Anticoagulant Adverse Reaction","enrollment":200},{"nctId":"NCT03642509","phase":"NA","title":"Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2019-01-01","conditions":"Atrial Fibrillation, Stroke","enrollment":750},{"nctId":"NCT06171984","phase":"","title":"Thrombophilia Assessment Under DOAC: Effectiveness of Activated Charcoal","status":"UNKNOWN","sponsor":"University Hospital, Strasbourg, France","startDate":"2022-07-19","conditions":"Thrombophilia","enrollment":200},{"nctId":"NCT06144866","phase":"","title":"Evaluataion of NOAC Levels in Acute Stroke","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2020-05-01","conditions":"Ischemic Stroke, Anticoagulant Adverse Reaction","enrollment":1000},{"nctId":"NCT02864758","phase":"","title":"Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-09-08","conditions":"Atrial Fibrillation","enrollment":99999},{"nctId":"NCT02744092","phase":"NA","title":"Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2016-12-13","conditions":"Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT)","enrollment":811},{"nctId":"NCT05022563","phase":"","title":"Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-31","conditions":"Venous Thromboembolism","enrollment":55759},{"nctId":"NCT03148457","phase":"NA","title":"Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2017-11-06","conditions":"Ischaemic Stroke","enrollment":2013},{"nctId":"NCT04679298","phase":"","title":"Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants Extended","status":"UNKNOWN","sponsor":"University Hospital Tuebingen","startDate":"2021-01-05","conditions":"Anticoagulation With Direct Oral Anticoagulants","enrollment":80},{"nctId":"NCT03441633","phase":"","title":"Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-02-18","conditions":"Atrial Fibrillation","enrollment":51690},{"nctId":"NCT04297150","phase":"","title":"Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..","status":"UNKNOWN","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2020-06-18","conditions":"Atrial Fibrillation","enrollment":700},{"nctId":"NCT03977363","phase":"","title":"The Portuguese Survey on Anticoagulated Patients Register (START-Portugal-Register)","status":"TERMINATED","sponsor":"CHAD","startDate":"2020-01-27","conditions":"Atrial Fibrillation, Venous Thromboembolism, Heart Valve Diseases or Prosthesis","enrollment":25},{"nctId":"NCT04195113","phase":"","title":"Perioperative Anticoagulant Use for Surgery Evaluation Emergency Registry","status":"COMPLETED","sponsor":"McMaster University","startDate":"2019-08-07","conditions":"Atrial Fibrillation, Venous Thromboembolism, Arterial Vascular Disease","enrollment":242},{"nctId":"NCT03572972","phase":"","title":"Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-01-31","conditions":"Atrial Fibrillation","enrollment":64684},{"nctId":"NCT04808934","phase":"","title":"NOAC Portuguese Real World Study","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2020-06-01","conditions":"Stroke, Systemic Embolism, Major Bleeding","enrollment":""},{"nctId":"NCT04002011","phase":"PHASE2","title":"DOAC Versus VKA After Cardiac Surgery","status":"WITHDRAWN","sponsor":"Laval University","startDate":"2022-03-09","conditions":"Anticoagulant-induced Bleeding","enrollment":""},{"nctId":"NCT02219984","phase":"","title":"START-Register: Survey on Anticoagulated Patients Register","status":"RECRUITING","sponsor":"GUALTIERO PALARETI","startDate":"2011-10","conditions":"Atrial Fibrillation, Venous Thromboembolism, Heart Valve Diseases or Prosthesis","enrollment":15410},{"nctId":"NCT01588119","phase":"","title":"Register for New Oral Anticoagulants","status":"UNKNOWN","sponsor":"GWT-TUD GmbH","startDate":"2011-11","conditions":"Anticoagulation Treatment","enrollment":5000},{"nctId":"NCT02353585","phase":"","title":"Novel Oral Anticoagulants in Stroke Patients","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2014-12","conditions":"Ischemic Stroke, Intracranial Hemorrhages","enrollment":1050},{"nctId":"NCT03292666","phase":"","title":"Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2010-01-01","conditions":"Venous Thromboembolism, Anticoagulants and Bleeding Disorders","enrollment":39603},{"nctId":"NCT04151680","phase":"","title":"Anticoagulation on Demand After Percutaneous Coronary Intervention in High Bleeding Risk Patients","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2019-12-01","conditions":"Ischemic Heart Disease, Atrial Fibrillation","enrollment":100},{"nctId":"NCT02666742","phase":"PHASE4","title":"DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation","status":"COMPLETED","sponsor":"Kansas City Heart Rhythm Institute","startDate":"2017-02-16","conditions":"Ventricular Tachycardia, Premature Ventricular Contraction, Stroke","enrollment":246},{"nctId":"NCT03942913","phase":"","title":"Prospective Real-world Registry Describing Treatment Regimens","status":"UNKNOWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2019-10-10","conditions":"Subject Under Anticoagulant","enrollment":573},{"nctId":"NCT05491460","phase":"PHASE1","title":"Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants Subjects","status":"UNKNOWN","sponsor":"Doasense GmbH","startDate":"2022-07-01","conditions":"Anticoagulant Therapy","enrollment":24},{"nctId":"NCT03181386","phase":"PHASE3","title":"Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2017-05-03","conditions":"Atrial Fibrillation, Periodontal Disease, Hemorrhage","enrollment":60},{"nctId":"NCT02640222","phase":"","title":"APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-01-01","conditions":"Anticoagulation","enrollment":321501},{"nctId":"NCT01999179","phase":"NA","title":"Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2014-06","conditions":"Venous Thrombosis, Neoplasms","enrollment":27},{"nctId":"NCT02754154","phase":"","title":"Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-12-31","conditions":"Atrial Fibrillation","enrollment":321182},{"nctId":"NCT03182829","phase":"","title":"In Vitro Diagnostic Test for DOAC in Urine","status":"COMPLETED","sponsor":"Doasense GmbH","startDate":"2018-08-22","conditions":"Anticoagulant Therapy","enrollment":880},{"nctId":"NCT03153150","phase":"PHASE3","title":"Start or STop Anticoagulants Randomised Trial (SoSTART)","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2018-03-28","conditions":"Intracranial Hemorrhages, Intracranial Hemorrhage, Hypertensive, Subarachnoid Hemorrhage","enrollment":203},{"nctId":"NCT05319340","phase":"NA","title":"I.M. Sechenov First Moscow State Medical University (Sechenov University)","status":"COMPLETED","sponsor":"I.M. Sechenov First Moscow State Medical University","startDate":"2014-01-15","conditions":"Anticoagulants","enrollment":1000},{"nctId":"NCT02286414","phase":"","title":"Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-02","conditions":"Atrial Fibrillation","enrollment":159},{"nctId":"NCT05027061","phase":"","title":"A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2021-04-02","conditions":"Non-Valvular Atrial Fibrillation (NVAF)","enrollment":11776},{"nctId":"NCT03965741","phase":"","title":"Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-05-30","conditions":"Venous Thromboembolism (VTE)","enrollment":97765},{"nctId":"NCT02701062","phase":"PHASE4","title":"AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)","status":"COMPLETED","sponsor":"AtriCure, Inc.","startDate":"2016-02","conditions":"Post-Operative Atrial Fibrillation","enrollment":562},{"nctId":"NCT04056143","phase":"","title":"Precision Medicine Platform for Novel Oral Anticoagulants","status":"UNKNOWN","sponsor":"Kaohsiung Medical University","startDate":"2019-01-02","conditions":"Anticoagulant Adverse Reaction","enrollment":500},{"nctId":"NCT02464488","phase":"","title":"New Oral Direct Anticoagulants in Patients 80 Years Old and Over : a Population Pharmacokinetics Study","status":"COMPLETED","sponsor":"Hôpital Charles Foix","startDate":"2015-01-01","conditions":"Atrial Fibrillation","enrollment":232}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":795,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pradaxa","Xarelto"],"phase":"marketed","status":"active","brandName":"Dabigatran; Rivaroxaban","genericName":"Dabigatran; Rivaroxaban","companyName":"University Hospital, Grenoble","companyId":"university-hospital-grenoble","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Both dabigatran and rivaroxaban are direct oral anticoagulants that inhibit key clotting factors to prevent blood clot formation. Used for Atrial fibrillation for stroke prevention, Deep vein thrombosis (DVT) treatment and prevention, Pulmonary embolism (PE) treatment and prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}